Comparison of efficacy and safety of salvage-line nivolumab monotherapy between 240 and 480 mg for advanced esophageal squamous cell carcinoma.

被引：0
|
作者：
Murashima, Yuko
Yamamoto, Shun
Hirose, Toshiharu
Kadono, Toru
Ikeda, Go
Ohara, Akihiro
Itoyama, Mai
Yokoyama, Kazuki
Honma, Yoshitaka
Ishiyama, Koshiro
Oguma, Junya
Daiko, Hiroyuki
Kato, Ken
机构：
[1] Natl Canc Ctr, Dept Head & Neck, Esophageal Med Oncol, Tokyo, Japan
[2] Natl Canc Ctr, Dept Esophageal Surg, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
317
引用
下载
收藏
页码：317 / 317
页数：1
相关论文
共 50 条
  • [41] A Prospective Clinical Study On The Efficacy And Safety Of Anlotinib In The Treatment Of Recurrent / Metastatic Advanced Esophageal Squamous Cell Carcinoma
    Li, K.
    Li, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E609 - E609
  • [42] The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma
    Shen, Dijian
    Chen, Qixun
    Wu, Jie
    Li, Jianqiang
    Tao, Kaiyi
    Jiang, Youhua
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (01) : 1 - 10
  • [43] Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma.
    Sheng, Liming
    Du, Xianghui
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma
    Zhao, Zheng
    Yin, Ming-Mei
    Zhao, Wei-Feng
    Wang, Chao-Jie
    MEDICINE, 2023, 102 (33) : E34794
  • [45] Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma
    Liu, Shixian
    Dou, Lei
    Wang, Kaixuan
    Shi, Zhao
    Wang, Ruixue
    Zhu, Xiaohong
    Song, Zehua
    Li, Shunping
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [46] Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma
    Hiroki Ishihara
    Toshio Takagi
    Tsunenori Kondo
    Hironori Fukuda
    Hidekazu Tachibana
    Kazuhiko Yoshida
    Junpei Iizuka
    Hirohito Kobayashi
    Masayoshi Okumi
    Hideki Ishida
    Kazunari Tanabe
    International Journal of Clinical Oncology, 2020, 25 : 705 - 712
  • [47] Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma
    Ishihara, Hiroki
    Takagi, Toshio
    Kondo, Tsunenori
    Fukuda, Hironori
    Tachibana, Hidekazu
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kobayashi, Hirohito
    Okumi, Masayoshi
    Ishida, Hideki
    Tanabe, Kazunari
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (04) : 705 - 712
  • [48] The association between smoking and LINE-1 hypomethylation (global DNA hypomethylation) in normal esophageal epithelium of patients with esophageal squamous cell carcinoma.
    Iwagami, Shiro
    Baba, Yoshifumi
    Watanabe, Masayuki
    Shigaki, Hironobu
    Miyake, Keisuke
    Ida, Satoshi
    Nagai, Yohei
    Ishimoto, Takatsugu
    Iwatsuki, Masaaki
    Sakamoto, Yasuo
    Miyamoto, Yuji
    Baba, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [49] Safety and efficacy of anti-EGFR monoclonal antibody(SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
    Ming Bai
    Meng Wang
    Ting Deng
    Yuxian Bai
    Kai Zang
    Zhanhui Miao
    Wenlin Gai
    Liangzhi Xie
    Yi Ba
    Cancer Biology & Medicine, 2022, (03) : 358 - 369
  • [50] Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
    Bai, Ming
    Wang, Meng
    Deng, Ting
    Bai, Yuxian
    Zang, Kai
    Miao, Zhanhui
    Gai, Wenlin
    Xie, Liangzhi
    Ba, Yi
    CANCER BIOLOGY & MEDICINE, 2022, 19 (03) : 358 - 369
12345